Drugs in the Pipeline
Phase 3 Study of ACZ885 for Children with Systemic Juvenile Idiopathic Arthritis
Novartis announced data from its Phase 3 study of ACZ885 (canakinumab) for the treatment of children with active systemic juvenile idiopathic arthritis (SJIA).